在遗传性性病的新兴疗法
Mallory L S Eisel1, Matthew Burns1, Tetsuo Ashizawa2
1Department of Neurology and the Fixel Institute for Neurological Disorders, University of Florida College of Medicine, Gainesville, FL, USA.
Trends in molecular medicine
|August 17, 2024
概括
研究人员正在探索遗传性 (HA) 的新疗法,重点是针对弗里德里希 (FRDA) 和多重胺的基因疗法. 虽然有希望的临床前策略存在,但需要进一步开发安全有效的临床应用.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 遗传性缩症 (HA) 涉及复杂的遗传机制,包括RNA和蛋白质水平的功能障碍.
- 临床前研究正在推进各种HA的治疗策略.
研究的目的:
- 审查目前关于弗里德里希动症 (FRDA) 和多重胺动症的翻译研究.
- 突出这些罕见的神经系统疾病开发有效治疗方法的进展和挑战.
主要方法:
- 基因编辑,基因/蛋白质替代和基因淘汰策略正在被调查.
- 治疗传递方法包括病毒载体,寡核酸,细胞透和合成转录因子.
主要成果:
- 对HA病理生理学的理解得到了改善,揭示了功能丧失和功能获取机制.
- 不同的临床前治疗方法显示出治疗HA的潜力.
结论:
- 对FRDA和多重氨酸氧症的翻译研究正在积极进行,但需要进一步发展.
- 确定安全的分子,优化输送和进行创新的临床试验是关键的下一步.
相关概念视频
01:24Parkinson's Disease: Treatment
240
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
240
01:22Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171